Announcement of Availability for Sacituzumab Govitecan
October 29, 2024
The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using sacituzumab govitecan (SG), a trophoblast antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), which is being researched by CTEP as an anticancer agent in collaboration with Gilead Sciences, Inc. CTEP may consider requests to support nonclinical, correlative-focused studies with SG on a case-by-case basis. All clinical and nonclinical, correlative-focused researchers interested in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).
All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
If you are a DFHCC Investigator interested in submitting an LOI using sacituzumab govitecan through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).
Questions may be addressed to Dr. Lorraine Pelosof (lorraine.pelosof@nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).